VRBPAC unanimously recommends monovalent, XBB lineage for next fall's Covid-19 vaccine campaign
The FDA’s Vaccines and Related Biological Products Advisory Committee met Thursday to assess whether the Covid-19 vaccine needs to be updated, with the committee voting 21-0 in favor of a new monovalent, XBB lineage for shots likely coming this fall.
Pfizer/BioNTech, Moderna and Novavax all presented on what they are likely to have ready in the coming months, with all three vaccines potentially ready as soon as later this summer. Pfizer, for instance, noted that they could have an XBB.1.5 monovalent version available as soon as the end of next month, or an XBB.1.16 monovalent vaccine in August.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.